{
  "abstract": "Hormone receptor-positive, human epidermal growth factor receptor 2-low (HER2-low) metastatic breast cancer (MBC) constitutes the predominant subtype of advanced breast cancer, with most patients eventually developing resistance to endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). This case report describes a 64-year-old woman with hormone receptor (HR)-positive, HER2-low MBC involving lung, pleural, and lymph node metastases who achieved a remarkable and sustained radiographic complete response (rCR) to palbociclib plus fulvestrant, followed by letrozole after fulvestrant injection intolerance. The patient exhibited near-complete regression of metastatic lesions within 18 months and maintained remission for over 6 years, far exceeding the typical median progression-free survival observed in clinical trials. The prolonged remission observed underscores the existence of biologically distinct tumor subsets with exceptional sensitivity to CDK4/6 inhibition, warranting investigation into underlying molecular mechanisms.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Breast Surgery, Pingxiang People's Hospital, Pingxiang, Jiangxi, China.",
    "Department of Pathology, Pingxiang People's Hospital, Pingxiang, Jiangxi, China."
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Mingzhi Cha"
    },
    {
      "affs": [
        0
      ],
      "name": "Hao Yi"
    },
    {
      "affs": [
        1
      ],
      "name": "HuiMing Li"
    },
    {
      "affs": [
        0
      ],
      "name": "Rongrong Peng"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0jg80bvzkg7dn.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1856673",
  "fulltext_url": "https://europepmc.org/articles/PMC13682961",
  "id": "0jg80bvzkg7dn",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://europepmc.org/article/MED/42908516",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Advanced Breast Cancer Therapies"
    ]
  ],
  "openalex": "W7220855780",
  "pdf_url": "https://europepmc.org/articles/PMC13682961?pdf=render",
  "pmcid": "PMC13682961",
  "pmid": "42908516",
  "published": "2026-10-07",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/0jg80bvzkg7dn.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:53Z",
      "native_id": "MED:42908516",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42908516"
    },
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1856673",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1856673/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2234-943X",
      "subfield": "oncology"
    }
  ],
  "title": "A surprising complete radiographic response to palbociclib plus endocrine therapy in an HR-positive, HER2-low lung, pleural, and lymph node metastatic breast cancer patient: a case report.",
  "title_text": "A surprising complete radiographic response to palbociclib plus endocrine therapy in an HR-positive, HER2-low lung, pleural, and lymph node metastatic breast cancer patient: a case report.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:13Z",
  "url": "https://research.draconitic.com/paper/0jg80bvzkg7dn",
  "venue": "Frontiers in oncology",
  "versions": []
}